MedTrace Logo

Florbetaben for Imaging of Vascular Amyloid

NCT06091319 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2026-05-08

No results posted yet for this study

Summary

The Primary Objective is to determine if a new nuclear tracer (named 18F-Florbetaben) used with nuclear imaging (PET imaging) can detect inflamed plaque in patients with recent ACS or stroke/TIA.

Conditions

  • Acute Coronary Syndrome
  • Stroke
  • Transient Ischemic Attack
  • Atherosclerosis of Artery

Interventions

PROCEDURE

[18F]-Florbetaben PET and CT imaging

\[18F\]-Florbetaben imaging to compare uptake in the culprit and non-culprit arteries.

Sponsors & Collaborators

  • Ottawa Heart Institute Research Corporation

    lead OTHER

Principal Investigators

  • Kevin E Boczar, MD · Ottawa Heart Institute Research Corporation

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-10-09
Primary Completion
2026-08-01
Completion
2026-08-01

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06091319 on ClinicalTrials.gov